Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > October 28, 2019
Daily News
October 28, 2019
- Pharma’s Downsizing Bandwagon Shows No Sign of Slowing, Companies Seeking Even Leaner Staff
October 28, 2019
- AbbVie Embarking on Work Style Reform for Sales Reps, Lets Staffers Pick Locations
October 28, 2019
- 1st Topical JAK Inhibitor in Line for Japan Approval in January
October 28, 2019
- Decision on Whether Antibiotics Are Manufactured in Japan or Overseas Should be Left to Drug Makers: Govt
October 28, 2019
- With European OK, Astellas’ Xospata Extends Lead over Daiichi Sankyo’s FLT3 Rival
October 28, 2019
- Mitsubishi Tanabe Ups H1 Earnings Forecast
October 28, 2019
- Academic Society Calls for Caution in Using Xofluza in Patients Under Age 12
October 28, 2019
- Nichi-Iko to Gradually Resume Cefazolin Supply from Nov. 25
October 28, 2019
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…